A5086094365- Colorectal Cancer Treatments and Studies
- Gastrointestinal Tumor Research and Treatment
- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Treatments and Mutations
- PI3K/AKT/mTOR signaling in cancer
- Cancer Treatment and Pharmacology
- Colorectal Cancer Surgical Treatments
- Platelet Disorders and Treatments
- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Colorectal and Anal Carcinomas
- Lymphoma Diagnosis and Treatment
- Metabolism, Diabetes, and Cancer
- Sarcoma Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Diabetes Treatment and Management
- Glioma Diagnosis and Treatment
- Biochemical and Molecular Research
- Cancer-related Molecular Pathways
- Melanoma and MAPK Pathways
- Cancer therapeutics and mechanisms
King Hussein Cancer Center
2018
The University of Texas MD Anderson Cancer Center
2009-2018
Jordan University of Science and Technology
2018
Weatherford College
2011
Moffitt Cancer Center
2005-2010
University of South Florida
2006-2010
Mount Sinai Hospital
2006-2009
Dana-Farber/Harvard Cancer Center
2009
University of Toronto
2009
Universitair Ziekenhuis Leuven
2009
The antiepidermal growth factor receptor (EGFR) antibody cetuximab shows activity in multiple epithelial tumor types; however, responses are seen only a subset of patients. This study was conducted to identify markers that associated with disease control patients treated cetuximab.One hundred ten metastatic colorectal cancer were enrolled onto monotherapy trial. Transcriptional profiling on RNA from mandatory pretreatment biopsies genes whose expression correlates best clinical responses....
Prolonged survival after two-stage resection (TSR) of advanced colorectal liver metastases (CLM) may be the result selection best responders to chemotherapy. The impact complete in this well-selected group is controversial.Data on 890 patients undergoing and 879 who received only chemotherapy for CLM were collected prospectively. We used intent-to-treat analysis evaluate underwent TSR. Additionally, we evaluated a cohort nonsurgically treated selected mirror TSR population: with liver-only...
To determine the maximum-tolerated dose (MTD) and assess safety, pharmacokinetics, preliminary evidence of antitumor activity YM155, a small-molecule inhibitor survivin.Patients with advanced solid malignancies or lymphoma were treated escalating doses YM155 administered by 168-hour continuous intravenous infusion (CIVI). Plasma urine samples assayed to pharmacokinetic parameters excretion.Forty-one patients received 127 cycles at ranging from 1.8 6.0 mg/m(2)/d CIVI every 3 weeks. Overall,...
This phase 1 study evaluated the pharmacokinetic and pharmacodynamic effects of cetuximab on patients with epithelial malignancies.Following a skin tumor biopsy, advanced malignancies were randomized to receive single dose at 50, 100, 250, 400, or 500 mg/m2 i.v. Repeat (days 2, 8, 15, 22) (day 8) biopsies obtained. Immunohistochemical expression epidermal growth factor receptor (EGFR) its pathway members was done biopsies. Blood samples obtained over 22 days for analyses. After day 22, all...
Patients with type II diabetes mellitus (DM) have an increased risk of adenomatous colorectal (CRC) polyps and CRC cancer. The use the anti-hyperglycemic agent metformin is associated a reduced incidence cancer-related deaths.
KRAS is the most commonly mutated oncogene in human tumors. KRAS-mutant cells may exhibit resistance to allosteric MEK1/2 inhibitor selumetinib (AZD6244; ARRY-142886) and AKT inhibitors (such as MK-2206), combination of which overcome both monotherapies.
There is an unmet clinical need for molecularly directed therapies available metastatic colorectal cancer. Comprehensive genomic profiling has the potential to identify actionable alterations in Through comprehensive we prospectively identified 6 RET fusion kinases, including two novel fusions of CCDC6-RET and NCOA4-RET, cancer (CRC) patients. kinases represent a class oncogenic driver CRC occurred at 0.2% frequency without concurrent mutations, KRAS, NRAS, BRAF, PIK3CA or other tyrosine...
Soft tissue sarcomas (STS) represent a diverse group of histologic subtypes with targetable molecular alterations, often treated as single disease. Sunitinib malate is multitargeted receptor tyrosine kinase inhibitor active in other solid tumors carrying similar alterations (i.e., imatinib mesylate-refractory gastrointestinal stromal tumors). This single-institution phase II study investigated the safety and efficacy sunitinib three common STS subtypes. Patients documented unresectable or...
Abstract Locally advanced rectal cancer is commonly treated with chemoradiation prior to total mesorectal excision ( TME ). Studies suggest that metformin may be an effective chemopreventive agent in this disease as well a possible adjunct current therapy. In study, we examined the effect of use on pathologic complete response pCR ) rates and outcomes cancer. The charts 482 patients locally adenocarcinoma from 1996 2009 were reviewed. Median radiation dose was 50.4 Gy (range 19.8–63)....
An intravenous formulated extract of the venom wild toad Bufo bufo gargarizans Cantor or melanostictus Schneider, huachansu, is currently used in China for treatment lung, liver, pancreatic, and colorectal cancers. We performed a randomised, single-blinded, phase II clinical study huachansu plus gemcitabine versus placebo patients with locally advanced and/or metastatic pancreatic adenocarcinomas.Patients tissue-proven adenocarinoma were randomly assigned to receive either 1000 mg m(-2) on...
KRAS mutations have been associated with lung metastases at diagnosis of metastatic colorectal cancer (mCRC), but the impact this mutation on subsequent development metastasis is unknown. We investigated as a predictor development.We retrospectively evaluated data from patients mCRC whose tumour was tested for 2008 to 2010. The relationships mutational status time-to-lung (TTLM) and overall survival (OS) were analysed.Of 494 identified, 202 (41%) had tumours mutation. shorter TTLM (median...
In Brief Objective: We hypothesized that metachronous colorectal liver metastases (CLM) have different biology after failure of oxaliplatin (FOLFOX) compared to 5-fluorouracil (5-FU) or no chemotherapy for adjuvant treatment cancer (CRC). Background: It is unclear whether patients treated with resection CLM FOLFOX CRC worse outcomes than those who received 5-FU chemotherapy. Methods: identified 341 underwent hepatectomy (disease-free interval ≥12 months, 1993–2010). Mass-spectroscopy...
Irinotecan is cytotoxic in patients with advanced colorectal cancer (CRC). SN-38 (10-hydroxy-7-ethyl-camptothecin) the active metabolite of irinotecan. Attachment polyethylene glycol (PEG) polymer chains (pegylation) to (EZN-2208) increases solubility, exposure, and half-life SN-38. Preclinical studies demonstrated superior vitro efficacy EZN-2208 when it was tested irinotecan-refractory human CRC cell lines.Patients metastatic or locally recurrent who had previously received 5-flurouracil...
This retrospective study aims to investigate the activity of retreatment with anti-EGFR-based therapies in order explore concept clonal evolution by evaluating impact prior and intervening time interval. Eighty-nine KRAS exon 2-wild-type metastatic colorectal patients were retreated on phase I/II clinical trials containing anti-EGFR after progressing cetuximab or panitumumab. Response therapy was defined retrospectively per physician-records as response stable disease ≥6 months....
To evaluate changes in circulating levels of soluble KIT (sKIT) extracellular domain as a potential biomarker for clinical outcome gastrointestinal stromal tumor patients treated with the multitargeted tyrosine kinase inhibitor sunitinib following imatinib failure previously reported phase III study.Patients received 50 mg/d (n = 243) or placebo 118) daily 6-week cycles (4 weeks on, 2 off treatment). Plasma sKIT were sampled every cycle 1 and on days 28 subsequent cycles; analyzed by ELISA;...
9513 Background: Sunitinib malate (previously known as SU11248) is an oral multitargeted tyrosine kinase inhibitor with both antitumor and antiangiogenic effects due to blockade of KIT, PDGFRs, VEGFRs, FLT3, RET. Initial results from this phase III trial showed sunitinib was associated significantly longer TTP than placebo in IM-resistant GIST pts. Methods: This double-blind, placebo-controlled, compared 50 mg/day (N=207) (N=105) or -intolerant Treatment administered 6-week cycles (4 weeks...
10524 Background: SU is an oral multitargeted tyrosine kinase inhibitor of KIT, PDGFRs, VEGFRs, FLT3, CSF-1R and RET, approved multinationally for treatment advanced GIST after IM failure. Interim analysis a double-blind, PL-controlled phase III trial in this pt population showed significant difference OS between pts randomized to (50 mg/d administered 6-wk cycles 4 wk on treatment, 2 off; N=207) or PL (N=105) favoring (HR 0.49; P=0.007), without medians having been reached. The study design...